SightLine Partners

SightLine is exclusively a healthcare specialist. Its entire mandate covers medical devices, diagnostics, digital health, and healthcare services. Unlike broad secondary platforms that buy LP stakes across all sectors, SightLine only transacts where its team has operating and clinical-domain expertise, which the firm argues produces better underwriting on regulatory and reimbursement risk.

SightLine's deal flow comes from being a known specialist in a narrow niche. When venture capital firms managing older med-tech funds face LP pressure to wind down, SightLine is a natural call. The firm also sources through its network of healthcare executives and its own portfolio company boards, which generate visibility into distressed cap tables before processes go broad.

The firm targets investments between $10 million and $30 million per deal. In secondary transactions, the check size can vary based on the LP stake being acquired. The Fund IV close at $305 million in 2024 suggests enough capital to lead transactions of that scale while reserving for follow-on investments in growth-stage recapitalizations.

SightLine's primary vehicle is a committed blind-pool fund series, but its direct secondary focus means it frequently transacts outside the auction processes common in large LP-stake trades. The firm can structure bespoke vehicles for single-asset GP-led recapitalizations, a capability that gives it flexibility when founders or management teams want to buy out legacy venture investors and bring in a committed healthcare backer.

The firm's healthcare focus is North American, with a historical concentration in the Upper Midwest — particularly Minnesota's dense medical-device corridor — and California. SightLine will invest nationally where the sector thesis holds, but its Bloomington headquarters gives it deep connectivity to the engineering and clinical talent pool around Minneapolis-St. Paul.

SightLine typically takes minority positions with board observation or board-level representation. Because the firm operates a sector-exclusive mandate, its reference network of med-tech operating executives and former FDA reviewers becomes part of the value proposition to portfolio companies, going beyond passive capital to assist with regulatory strategy, reimbursement coding, and commercial scaling.

Yes. In October 2024, the firm announced the final close of SightLine Healthcare Fund IV at $305 million, exceeding its $250 million target. As of early 2026, the fund is actively deploying capital into both secondary purchases and growth-stage healthcare investments.